Iantrek Corporation

About Iantrek Corporation

Iantrek is a company dedicated to meaningful innovation in bio-interventional ophthalmic surgery, focusing on developing next-generation technologies for total-outflow enhancement in glaucoma treatment. Their mission is to redefine expectations in microinterventional ophthalmic surgery.

Products & Services

CycloPen™ Microinterventional Cyclodialysis System:Ergonomically designed for the controlled creation or modification of a cyclodialysis to enhance uveoscleral outflow.

AlloFlo™:A bio-interventional solution designed to naturally enhance uveo-scleral outflow through precision scleral reinforcement.

C-Rex™:Transforms goniotomy with a fully circumferential, excisional, and titratable design for micro-interventional surgery.

Specialties

Microinterventional Ophthalmic Surgery Glaucoma Surgical Technologies Bio-Interventional Solutions Uveoscleral Outflow Enhancement

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 42000000 MR: - FA: $42 million FAN: 42000000	D: 2025-08-20 FD: 2025-08-20	6 investors

Series C Latest

2025-08-20

$42.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sean Ianchulev

Chairman of the Board, Professor of Ophthalmology at New York Eye and Ear of Mount Sinai, CMO

R

Robert Weinreb

Chairman and Director, Shiley Eye Institute

T

Toby Tyson

Board Member

I

Ike Ahmed

Chief Medical Officer

C

Chang

Advisor, Past President of ASCRS

A

Adam Szaronos

CEO

View 8 more team members with Pro

Unlock Full Team Directory

Recent News